Allergy Therapeutics (LON:AGY) Shares Down 11.3% – What’s Next?

Allergy Therapeutics plc (LON:AGY) shares fell 11.3% during trading on Wednesday . The stock traded as low as GBX 6.18 and last traded at GBX 6.30. Approximately 225,345 shares traded hands during mid-day trading, a decline of 17% from the average daily volume of 271,766 shares. The stock had previously closed at GBX 7.10.

Allergy Therapeutics Stock Down 11.3%

The company has a market capitalization of £398.95 million, a P/E ratio of -6.49, a PEG ratio of -30.70 and a beta of 0.85. The firm’s 50 day moving average price is GBX 9.07 and its two-hundred day moving average price is GBX 10.34. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%.The business had revenue of GBX 3,628 million for the quarter. Equities research analysts forecast that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.